DDInter1266 DDInter1335
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
Naproxen {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Naproxen {u} (Compound) downregulates {v} (Gene) CANT1
CANT1 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may lead to a major life threatening interaction when taken with {v} Omacetaxine mepesuccinate
Naproxen {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) HIST1H2BK
HIST1H2BK {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Naproxen {u} (Compound) downregulates {v} (Gene) CANT1
CANT1 {u} (Gene) is regulated by {v} (Gene) HIST1H2BK
HIST1H2BK {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Naproxen {u} (Compound) resembles {v} (Compound) Suprofen
Suprofen {u} (Compound) resembles {v} (Compound) Bromfenac
Bromfenac {u} may lead to a major life threatening interaction when taken with {v} Omacetaxine mepesuccinate
Naproxen {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} (Compound) downregulates {v} (Gene) RRP12
RRP12 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} (Compound) downregulates {v} (Gene) TIMELESS
TIMELESS {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Naproxen {u} (Compound) resembles {v} (Compound) Nabumetone
Nabumetone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metformin
Metformin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Naproxen (Compound) binds PTGS2 (Gene) and Naproxen (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Naproxen (Compound) downregulates CANT1 (Gene) and CANT1 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Naproxen (Compound) binds PTGS2 (Gene) and Naproxen (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is regulated by HIST1H2BK (Gene) and HIST1H2BK (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Naproxen (Compound) downregulates CANT1 (Gene) and CANT1 (Gene) is regulated by HIST1H2BK (Gene) and HIST1H2BK (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Naproxen (Compound) resembles Suprofen (Compound) and Suprofen (Compound) resembles Bromfenac (Compound) and Bromfenac may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Naproxen (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen (Compound) downregulates RRP12 (Gene) and RRP12 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin (Compound) downregulates TIMELESS (Gene) and TIMELESS (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Naproxen (Compound) resembles Nabumetone (Compound) and Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate